Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares Outstanding
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Debt Repayments: 2015-2019

Historic Long-Term Debt Repayments for Enanta Pharmaceuticals (ENTA) over the last 4 years, with Sep 2019 value amounting to $22,000.

  • Enanta Pharmaceuticals' Long-Term Debt Repayments rose 10.00% to $22,000 in Q3 2019 from the same period last year, while for Sep 2019 it was $86,000, marking a year-over-year increase of 8.86%. This contributed to the annual value of $86,000 for FY2019, which is 8.86% up from last year.
  • According to the latest figures from Q3 2019, Enanta Pharmaceuticals' Long-Term Debt Repayments is $22,000, which was down 0.00% from $22,000 recorded in Q2 2019.
  • Over the past 5 years, Enanta Pharmaceuticals' Long-Term Debt Repayments peaked at $22,000 during Q2 2019, and registered a low of $16,000 during Q4 2015.
  • Over the past 3 years, Enanta Pharmaceuticals' median Long-Term Debt Repayments value was $20,000 (recorded in 2018), while the average stood at $20,000.
  • Data for Enanta Pharmaceuticals' Long-Term Debt Repayments shows a peak YoY increased of 12.50% (in 2016) over the last 5 years.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Long-Term Debt Repayments stood at $16,000 in 2015, then grew by 12.50% to $18,000 in 2016, then climbed by 5.56% to $19,000 in 2017, then increased by 10.53% to $21,000 in 2018, then increased by 10.00% to $22,000 in 2019.
  • Its Long-Term Debt Repayments stands at $22,000 for Q3 2019, versus $22,000 for Q2 2019 and $21,000 for Q1 2019.